Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 78 results.
LastUpdate Updated on 22/11/2026 [07:41:00]
pdfxls
previousPage Results 25 to 50 of 78 nextPage  

Application of ANKRD23 inhibitor in preparation of products for preventing and treating cardiac hypertrophy and/or heart failure

Publication No.:  CN122768417A 18/09/2026
Applicant: 
THE 2ND AFFILIATED HOSPITAL OF WMU YUYING CHILDRENS HOSPITAL OF WMU
\u6E29\u5DDE\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u7B2C\u4E8C\u533B\u9662\uFF08\u6E29\u5DDE\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u80B2\u82F1\u513F\u7AE5\u533B\u9662\uFF09
CN_122768417_A

Absstract of: CN122768417A

The invention provides application of an ANKRD23 inhibitor in preparation of products for preventing and treating cardiac hypertrophy and/or heart failure, and belongs to the technical field of biological medicine. The invention provides application of an ANKRD23 inhibitor in preparation of products for preventing and treating cardiac hypertrophy and/or heart failure. Expression up-regulation of ANKRD23 in myocardial hypertrophy tissues and myocardial cells is proposed for the first time, and myocardial hypertrophy and cell apoptosis can be relieved by inhibiting ANKRD23 in vivo and in vitro. In addition, the invention proposes that ANKRD23 promotes the cardiac hypertrophy degree and induces cell apoptosis by activating a TAK1-P38MAPK/JNK signal channel for the first time, and reveals the important effect of an ANKRD23-TAK1 axis in cardiac hypertrophy for the first time. The result not only provides a new visual angle for understanding the effect of the ANKRD23 in the cardiac hypertrophy process, but also prompts that the ANKRD23 can become a new target for treatment intervention of pathological cardiac hypertrophy and heart failure.

PRDX4-based PASC-related cardiovascular system symptom risk assessment application

Publication No.:  CN122772976A 18/09/2026
Applicant: 
CHINA JAPAN FRIENDSHIP HOSPITAL CHINA JAPAN FRIENDSHIP INST OF CLINICAL MEDICINE
\u4E2D\u65E5\u53CB\u597D\u533B\u9662\uFF08\u4E2D\u65E5\u53CB\u597D\u4E34\u5E8A\u533B\u5B66\u7814\u7A76\u6240\uFF09
CN_122772976_PA

Absstract of: CN122772976A

The invention relates to the technical field of biological medicine, in particular to PRDX4-based PASC related cardiovascular system symptom risk assessment application. The invention provides a risk assessment system taking PRDX4 as a core molecular marker, and the system can provide objective and quantifiable molecular level reference basis for risk assessment of PASC-related cardiovascular system symptoms under the condition that sufficient explanation is difficult to provide by a conventional detection means.

MBL2 inhibitor and application thereof in treatment of ejection fraction retention type heart failure

Publication No.:  CN122750841A 15/09/2026
Applicant: 
UNIV SCIENCE & TECHNOLOGY CHINA
\u4E2D\u56FD\u79D1\u5B66\u6280\u672F\u5927\u5B66
CN_122750841_PA

Absstract of: CN122750841A

The invention belongs to the field of biological medicine and disease diagnosis, and particularly relates to an MBL2 inhibitor and application thereof in treatment of ejection fraction retention type heart failure. The invention provides an MBL2 inhibitor, the MBL2 inhibitor is an MBL2 silencing preparation, the MBL2 silencing preparation is siRNA and/or shRNA, the siRNA comprises three pairs of siRNA double strands targeting an Mbl2 gene, nucleotide sequences of positive-sense strands and antisense strands of the siRNA double strands are respectively as shown in SEQ ID NO: 1-6 and are mixed according to a molar ratio of 1: 1: 1, a nucleotide sequence of the shRNA is as shown in SEQ ID NO: 9, and a nucleotide sequence of the shRNA is as shown in SEQ ID NO: 6. The invention also discloses application of the MBL2 inhibitor in preparation of a medicine for treating and/or preventing heart failure. The MBL2 can be used as a potential diagnosis marker and a treatment target of ejection fraction retention type heart failure, and a new thought and an experimental basis are provided for clinical diagnosis and treatment of HFpEF.

Application of SIRT7 in vascular endothelial cells, medicine screening method, medicine composition, kit and model construction method

Publication No.:  CN122750834A 15/09/2026
Applicant: 
UNIV SHENZHEN
\u6DF1\u5733\u5927\u5B66
CN_122750834_PA

Absstract of: CN122750834A

The invention provides application of SIRT7 in vascular endothelial cells, a medicine screening method, a medicine composition, a kit and a model construction method. The invention discloses application of SIRT7 in vascular endothelial cells as a drug target in preparation of drugs for preventing, delaying or treating brain aging and/or vascular dementia. The SIRT7 in vascular endothelial cells is used as a biomarker to be applied to preparation of a diagnostic reagent or a kit for evaluating brain aging degree or vascular dementia risk.

Medical application of SGCD in prevention or treatment of abdominal aortic aneurysm

Publication No.:  CN122721633A 11/09/2026
Applicant: 
GENERAL HOSPITAL OF NORTHERN THEATER COMMAND OF PLA
\u4E2D\u56FD\u4EBA\u6C11\u89E3\u653E\u519B\u5317\u90E8\u6218\u533A\u603B\u533B\u9662
CN_122721633_PA

Absstract of: CN122721633A

The invention relates to the technical field of biological medicine, and particularly discloses medical application of SGCD in prevention or treatment of abdominal aortic aneurysm. Experiments prove that the SGCD expression is obviously reduced in the whole AAA generation and development process, and the SGCD is mainly highly expressed in vascular smooth muscle cells of human and mouse aortic tissues. An SGCD mouse in-vivo smooth muscle specific overexpression or low expression model is constructed by adopting caudal vein injection AAV virus, and it is found that in-vivo smooth muscle specific knock-down SGCD of a mouse remarkably aggravates formation and development of AAA, and smooth muscle specific overexpression SGCD remarkably relieves formation and development of AAA. The invention reveals that SGCD plays an important protective role in the occurrence and development process of AAA for the first time, can be used as a new target for preventing or treating AAA, provides a new target for the development of targeted drugs for the disease, has an important clinical application prospect, and provides a brand new drug intervention strategy for the clinical treatment of AAA.

Biomarker combination for diagnosing smoke disease and application thereof

Publication No.:  CN122727375A 11/09/2026
Applicant: 
ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY
\u6B66\u6C49\u5927\u5B66\u4E2D\u5357\u533B\u9662
CN_122727375_PA

Absstract of: CN122727375A

The invention discloses a biomarker combination for diagnosing smoke disease and application thereof. The biomarker combination is a combination of (a) 10 diagnostic genome segments or (b) 10 prognostic genome segments which are respectively used for distinguishing smoke disease and atherosclerotic cerebrovascular disease and predicting the advantages and disadvantages of postoperative collateral circulation formation of smoke disease patients. Based on a circulating free DNA methylation spectrum, the methylation level of a genome segment in peripheral blood is detected through TAPS sequencing, and a risk score is calculated in combination with a logistic regression model. The AUC of the diagnosis model in the discovery queue reaches 0.923, and the AUC in the external verification queue is 0.822; the AUC of the prognosis model in the discovery queue is 0.907, and the AUC of the prognosis model in the external verification queue is 0.854. According to the invention, noninvasive liquid biopsy of smoke diseases is realized for the first time, an epigenetic tool is provided for accurate differential diagnosis and individualized operation decision of smoke diseases, and the method has important clinical application value.

Cyclic non-coding RNA (Ribonucleic Acid) gene and application of small interfering RNA of cyclic non-coding RNA gene in preparation of medicine for inhibiting cardiac fibrosis

Publication No.:  CN122727239A 11/09/2026
Applicant: 
SHANGHAI EAST HOSPITAL TONGJI UNIV AFFILIATED EAST HOSPITAL
\u4E0A\u6D77\u5E02\u4E1C\u65B9\u533B\u9662\uFF08\u540C\u6D4E\u5927\u5B66\u9644\u5C5E\u4E1C\u65B9\u533B\u9662\uFF09
CN_122727239_PA

Absstract of: CN122727239A

The invention provides a cyclic non-coding RNA (Ribonucleic Acid) gene. The nucleotide sequence of the cyclic non-coding RNA gene is shown as SEQ ID NO. 1. The invention also provides an RNA intervention molecule which can specifically target circHFR and reduce circHFR expression, and the nucleotide sequences of the positive-sense strand and the antisense strand of the RNA intervention molecule are respectively shown as SEQ ID NO.3 and SEQ ID NO.4. The invention also provides an RNA intervention molecule which can specifically target circHFR and reduce circHFR expression. The invention also provides a pharmaceutical composition containing the RNA intervention molecule, and also provides an application of the pharmaceutical composition in preparation of drugs for treating cardiac fibrosis. The annular non-coding RNA gene provided by the invention can be used as a novel molecular target for intervening cardiac fibrosis, and the circHFR-targeted RNA intervening molecule can be used for preparing a medicine for treating cardiac fibrosis.

Application of lncRNA in preparation of medicine for treating cerebral arterial thrombosis neuronal ferroptosis

Publication No.:  CN122721448A 11/09/2026
Applicant: 
UNIV KUNMING MEDICAL
\u6606\u660E\u533B\u79D1\u5927\u5B66
CN_122721448_A

Absstract of: CN122721448A

The invention belongs to the technical field of biological medicines, and particularly discloses application of lncRNA in preparation of a medicine for treating cerebral arterial thrombosis neuronal ferroptosis. The nucleotide sequence of the lncRNA is as shown in SEQ ID NO: 1, and the lncRNA can play a multi-layer protection role in cerebral arterial thrombosis induced neuronal ferroptosis: the lncRNA can negatively regulate and control the expression of ferroptosis promoting genes Sat1 and Ptgs2, positively regulate and control the expression of an anti-ferroptosis gene Gpx4, remarkably improve the mitochondrial morphological abnormality, reduce the lipid peroxidation level and oxidative stress injury, and inhibit the cerebral arterial thrombosis induced neuronal ferroptosis, so that the lncRNA can be used for treating cerebral arterial thrombosis induced neuronal ferroptosis caused by cerebral arterial thrombosis induced neuronal ferroptosis. The homeostasis of iron ions in cells is regulated, excessive accumulation of the iron ions is inhibited, the functions of neurons are maintained, and the cell survival rate is improved. The invention provides a feasible strategy for developing potential treatment medicines for cerebral arterial thrombosis neuronal ferroptosis, is simple and convenient to operate, strong in targeting property and remarkable in curative effect, and has important clinical transformation value and medicine research and development guiding significance.

Molecular identification of cardiomyocytes for cardiac cell therapy

Publication No.:  CN122742877A 11/09/2026
Applicant: 
BLUE ROCK THERAPEUTICS LTD
\u84DD\u5CA9\u6CBB\u7597\u6709\u9650\u516C\u53F8
CN_122742877_PA

Absstract of: CN122742877A

The present disclosure relates generally to methods of screening and preparing cardiac cell therapies having a low risk of causing graft-induced arrhythmia.

Diagnostic, Prognostic And Therapeutic Uses Of Long Noncoding RNAs For Heart Disease And Regenerative Medicine

Publication No.:  US20260265829A1 10/09/2026
Applicant: 
UNIV DE LAUSANNE [CH]
UNIVERSITE DE LAUSANNE
US_20260265829_A1

Absstract of: US20260265829A1

Provided herein are lncRNAs and methods for diagnosing cardiac pathologies in a subject. Also provided are methods for treating a cardiac pathology in a subject comprising administering to said subject an effective amount of a modulator of one or more lncRNAs.

ZBTB16 AS A FACTOR FOR CARDIAC AGING AND DISEASE

Publication No.:  EP4802275A1 09/09/2026
Applicant: 
JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN [DE]
Johann-Wolfgang-Goethe-Universit\u00E4t Frankfurt am Main
WO_2025093713_PA

Absstract of: WO2025093713A1

The present invention relates to a method for identifying a compound that increases the expression, amount and/or biological activity of the gene ZBTB16 in a cell of a subject, in particular a cardiac cell. Further provided are pharmaceutical compositions comprising compounds that increase the expression, amount and/or biological activity of the gene ZBTB 16 in a cell of a subject for use in medicine, in particular for use in the prevention or treatment of cardiovascular pathologies in a subject, in particular age-induced diastolic dysfunctions. Further provided are diagnostic methods, and kits.

Application of NDUFB9 gene in prevention and/or treatment of atherosclerosis

Publication No.:  CN122701872A 08/09/2026
Applicant: 
UNIV HUNAN MEDICINE
\u6E56\u5357\u533B\u836F\u5B66\u9662
CN_122701872_PA

Absstract of: CN122701872A

The invention belongs to the technical field of biological medicines, and relates to application of an NDUFB9 gene in prevention and/or treatment of atherosclerosis. The key protection effect of the NDUFB9 gene in pyroptosis and atherosclerosis of vascular endothelial cells is found for the first time, and the molecular mechanism of the NDUFB9 gene is clarified. Based on the discovery, the invention provides an application of a substance for up-regulating and/or improving the expression quantity of the NDUFB9 gene and/or NDUFB9 protein in preparation of a medicine for preventing and/or treating atherosclerosis. By directly targeting a TMAO pathogenic pathway, the vascular endothelial function is repaired from an initial link, the defect that an existing medicine cannot block TMAO-mediated endothelial injury is overcome, and a brand-new target is provided for prevention and treatment of atherosclerosis.

Application of ZBP1 or ZBP1 coded protein in preparation of product for diagnosing sepsis cardiomyopathy

Publication No.:  CN122706822A 08/09/2026
Applicant: 
TIANJIN THIRD CENTRAL HOSPITAL
\u5929\u6D25\u5E02\u7B2C\u4E09\u4E2D\u5FC3\u533B\u9662
CN_122706822_PA

Absstract of: CN122706822A

The invention provides application of ZBP1 or ZBP1-coded protein in preparation of a product for diagnosing sepsis cardiomyopathy, and relates to the technical field of biological medicine. Through transcriptome sequencing analysis on a sepsis cardiomyopathy model, a variety of programmed cell death related pathways are found to be activated. The ZBP1 is further obtained by analyzing and screening the intersection of the differentially expressed gene and the generic apoptosis related gene set, and the ZBP1 has an up-regulation trend in the model. Verification is carried out through an in-vivo myocardial cell specific Zbp1 gene knockout model and an in-vitro myocardial cell knockout experiment, and the result shows that regulation and control of ZBP1 expression can influence expression of various programmed cell death related molecules and is related to myocardial damage and inflammatory response. The invention prompts that ZBP1 may participate in the pan-apoptosis process, and provides a new potential molecular target for sepsis cardiomyopathy.

Primer group and kit for simultaneously detecting multiple genetic diseases of cats and application of primer group and kit

Publication No.:  CN122686812A 04/09/2026
Applicant: 
MENGDUN BIOTECHNOLOGY SUZHOU CO LTD
\u840C\u76FE\u751F\u7269\u79D1\u6280\uFF08\u82CF\u5DDE\uFF09\u6709\u9650\u516C\u53F8
CN_122686812_A

Absstract of: CN122686812A

The invention provides a primer group and a kit for simultaneously detecting various genetic diseases of cats and application of the primer group and the kit, and belongs to the technical field of biology. The primer group comprises 9 pairs of specific primers used for multiplex PCR amplification, and can simultaneously amplify 9 target areas of 7 genetic diseases related to cat progressive retinal atrophy (rdAc), pyruvate kinase deficiency, polycystic nephropathy (PKD1), hypertrophic cardiomyopathy (A31P), fold ear gene (osteochondral dysplasia), cat spinal muscular atrophy and alpha-mannoside storage disease. The invention also provides a kit containing the primer group and a detection method based on multiple PCR (Polymerase Chain Reaction) combined with a three-generation nanopore sequencing technology. According to the method, after multiple amplification is completed in a reaction tube, all amplicons are sequenced through a nanopore sequencing platform, and various variation types such as point mutation, insertion, deletion and the like of each target gene are comprehensively detected at a time by utilizing the advantage of long reading length. The kit has the advantages of high throughput, comprehensive detection, simplicity and convenience in operation, high specificity, wide applicability and the like, and can be widely applied to clinical auxiliary diagnosis, large-scale screening and scientific breeding guidance of cat genetic diseases.

ECOBIOLOGICAL COMPOSITION CAPABLE OF PREVENTING AND TREATING REDNESS, SIGNS OF SKIN AGEING, AND VASCULAR ANOMALIES

Publication No.:  EP4798157A1 02/09/2026
Applicant: 
THOREL JEAN NOEL [FR]
NAOS INST OF LIFE SCIENCE [FR]
Thorel, Jean-No\u00EBl
NAOS Institute of Life Science
FR_3154611_A1

Absstract of: WO2025088286A1

The invention relates to a cosmetic composition, advantageously an ecobiological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by general formula (I), in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an α-amino acid selected from the group consisting of: tryptophan, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The invention also relates to the use of the cosmetic composition for combatting skin redness and/or skin ageing; to the use thereof for preventing and/or combatting cutaneous hypervascularisation and/or skin inflammation and/or rosacea; and to a method for selecting compounds suitable for preventing and/or combatting these conditions.

Application of 3-indolebutyric acid in preparation of medicine for treating chronic heart failure

Publication No.:  CN122664985A 01/09/2026
Applicant: 
INST OF LABORATORY ANIMAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
\u4E2D\u56FD\u533B\u5B66\u79D1\u5B66\u9662\u533B\u5B66\u5B9E\u9A8C\u52A8\u7269\u7814\u7A76\u6240
CN_122664985_PA

Absstract of: CN122664985A

The invention discloses application of 3-indolebutyric acid in preparation of a medicine for treating chronic heart failure, belongs to the technical field of disease detection and biological medicine, and finds that the 3-IBA level in blood plasma of a heart failure patient is remarkably reduced for the first time, and the 3-indolebutyric acid can be used as an auxiliary diagnosis and risk assessment marker of the chronic heart failure. The 2, 3-IBA metabolite can be specifically combined and activate an AhR target spot, related signal channels in myocardial tissues are accurately regulated and controlled, non-specific effects on other tissues and organs are avoided, and side effects are reduced; by activating AhR to up-regulate SIRT3, inhibit NNMT and enhance NAM and NAD < + >/NADH circulation, myocardial mitochondrial energy metabolism is improved fundamentally, oxidative stress is relieved, chronic inflammatory response is inhibited, ventricular remodeling is reversed, and etiological treatment of heart failure is achieved.

Pharmaceutical application of sodium ferulate for resisting doxorubicin cardiotoxicity based on multi-modal fusion and cardiac protection drug screening system and method

Publication No.:  CN122664974A 01/09/2026
Applicant: 
LIANWU JINNUO SHANGHAI BIOTECHNOLOGY CO LTD
\u8054\u6B66\u91D1\u8BFA\uFF08\u4E0A\u6D77\uFF09\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
CN_122664974_A

Absstract of: CN122664974A

The invention discloses application of sodium ferulate in preparation of a medicine for preventing and/or treating doxorubicin-induced cardiotoxicity, and a cardiac protection medicine screening system and method based on multi-modal fusion. The invention systematically proves that the sodium ferulate has a remarkable dose-dependent protective effect on doxorubicin-induced cardiotoxicity in a specific dose range, and provides a complete living body quantitative evidence chain from phenotype to molecular mechanism. The invention illustrates that sodium ferulate plays a role in protecting the heart through a dual-channel synergistic regulation mechanism of synergistically activating an Nrf2/HO-1/Sod2 antioxidant channel and inhibiting a Bax/Caspase-3/p53 apoptosis channel. The invention further constructs a multi-modal fusion heart protection drug screening system, the system organically fuses three technical means of AI image quantitative analysis, light wave nondestructive testing and transcriptome signal path analysis through a weighted comprehensive scoring algorithm, and rapid, accurate and automatic evaluation of the heart protection activity of candidate drugs is achieved. The screening accuracy is improved to 95% or above, and the screening flux is improved to about 500 samples per day. A safe candidate drug is provided for adriamycin clinical cardiotoxicity protection, a standardized technical platform is provided for efficient and intelligent screening of heart protec

Application of exosome miR-223-3p in preparation of medicine for treating myocardial injury caused by sepsis

Publication No.:  CN122665012A 01/09/2026
Applicant: 
THE FIRST AFFILIATED HOSPITAL OF SHIHEZI UNIV
\u77F3\u6CB3\u5B50\u5927\u5B66\u7B2C\u4E00\u9644\u5C5E\u533B\u9662
CN_122665012_PA

Absstract of: CN122665012A

The invention discloses an application of exosome miR-223-3p in preparation of a medicine for treating myocardial injury caused by sepsis, and relates to the technical field of biological medicine, the application of the exosome miR-223-3p in preparation of the medicine for treating myocardial injury caused by sepsis comprises the following steps: the exosome miR-223-3p inhibits ferroptosis of myocardial cells by regulating a Keap1/Nrf2 signal channel, and the application of the exosome miR-223-3p in preparation of the medicine for treating myocardial injury caused by sepsis in preparation of the medicine for treating myocardial injury caused by sepsis in preparation of the medicine for treating myocardial injury caused by sepsis in preparation of the medicine for treating myocardial injury caused by sepsis in preparation of the medicine. The invention relates to application of a reagent for detecting the expression level of exosome miR-223-3p in preparation of a kit for sepsis myocardial injury diagnosis or prognosis evaluation. The invention discloses a new application of the exosome miR-223-3p in the treatment of myocardial injury caused by sepsis by inhibiting ferroptosis through a Keap1/Nrf2 pathway. The invention provides application of a reagent for detecting the expression level of exosome miR-223-3p in preparation of a sepsis myocardial injury diagnosis or prognosis evaluation kit.

Application of miR-1839-5p in preparation of medicine for preventing or treating pathological cardiac hypertrophy

Publication No.:  CN122665011A 01/09/2026
Applicant: 
UNIV SHANGHAI ENG SCIENCE
\u4E0A\u6D77\u5DE5\u7A0B\u6280\u672F\u5927\u5B66
CN_122665011_PA

Absstract of: CN122665011A

The invention discloses application of miR-1839-5p in preparation of a medicine for preventing or treating pathological cardiac hypertrophy, and belongs to the technical field of biological medicine. The miR-1839-5p is used for preparing the medicine for preventing or treating pathological cardiac hypertrophy, and the nucleotide sequence of the miR-1839-5p is as shown in SEQ ID NO. 1. The miR-1839-5p shows down-regulation expression characteristics in a pathological cardiac hypertrophy model, inhibition of expression of the miR-1839-5p can induce pathological cardiac hypertrophy, overexpression of the miR-1839-5p can significantly inhibit high pathological cardiac hypertrophy, and the miR-1839-5p is expected to serve as a treatment target to develop drugs for pathological cardiac hypertrophy and has important clinical application prospects.

CTRTS, simulant and application thereof

Publication No.:  CN122648415A 28/08/2026
Applicant: 
QINGDAO UNIV
\u9752\u5C9B\u5927\u5B66
CN_122648415_PA

Absstract of: CN122648415A

The invention belongs to the field of gene drugs, and particularly relates to CTRTS, a simulant and application of the CTRTS and the simulant. The nucleotide sequence of the CTRTS is as shown in SEQ ID NO. 1. The CTRTS simulant is CTRTS Agomir, and the nucleotide sequence of the CTRTS simulant is shown as SEQ ID NO. 2. Researches find that when doxorubicin induces cardiotoxicity, the expression level of CTRTS is reduced; overexpression of CTRTS can significantly inhibit adriamycin-induced cardiotoxicity, and plays an important role in myocardial cell death regulation and control. Existing drugs are limited in treatment effect, so that CTRTS plays an important role in myocardial cell death regulation and control and can participate in treatment of regulating and controlling the myocardial cell death process and regulating and controlling doxorubicin induced cardiotoxicity, and therefore the clinical prognosis effect of CTRTS is achieved.

Multiple isothermal amplification detection method for VTE high-risk individual recognition and multiple isothermal amplification detection kit for VTE high-risk individual recognition

Publication No.:  CN122648563A 28/08/2026
Applicant: 
GUANGZHOU ZHILI MEDICAL DIAGNOSTIC TECH CO LTD
GUANGZHOU PANYU HOSPITAL OF TCM
\u5E7F\u5DDE\u77E5\u529B\u533B\u5B66\u8BCA\u65AD\u6280\u672F\u6709\u9650\u516C\u53F8
\u5E7F\u5DDE\u5E02\u756A\u79BA\u533A\u4E2D\u533B\u9662
CN_122648563_PA

Absstract of: CN122648563A

The invention relates to the technical field of molecular diagnosis and genotyping, in particular to a VTE high-risk individual recognition multiple isothermal amplification detection method and a VTE high-risk individual recognition multiple isothermal amplification detection kit, and the method comprises the following steps: constructing a 4-7 SNP site detection panel comprising SERPINC1 antithrombin defect variation, PROC protein C defect hot spot (p.Arg189Trp) and at least one SNP site in MTHFR, PAI-1, FGG and ABO; designing an allele-specific forward primer pair, a universal reverse primer and a tetrahydrofuran-containing site probe of a 3'terminal plus a reciprocal second or third artificial mismatch double-mismatch anchoring framework for each SNP site, wherein the allele-specific forward primer pair and the universal reverse primer pair are arranged on the 3 'terminal plus the reciprocal second or third artificial mismatch double-mismatch anchoring framework; and the Chinese population queue OR value weighted scoring model is adopted to output a risk layering result, so that the method is rapid in detection, multiple in single tube, small in sample consumption and optional in zero instrument, and is suitable for rapid screening of the genetic risk of the Chinese population primary medical venous thromboembolism.

Endothelial-derived foam cell specific marker and application thereof

Publication No.:  CN122648579A 28/08/2026
Applicant: 
SICHUAN UNIV
\u56DB\u5DDD\u5927\u5B66
CN_122648579_PA

Absstract of: CN122648579A

The invention discloses an endothelial-derived foam cell specific marker and application thereof, and belongs to the technical field of markers. By constructing a cell and animal model and combining with a clinical sample to carry out multi-level experiments, it is proved that AKR1B1 only has high specific expression in endothelial-derived foam cells, and AKR1B1 can be used as a specific marker of eFCs. Therefore, the invention provides a tracing marker for revealing the dynamic evolution process of endothelial cell foaming and the effect of the endothelial cell foaming in the atherosclerosis progress, and provides a new theoretical basis and a potential treatment target for accurate diagnosis and targeted intervention of diseases.

GENOMIC AND METHYLATION BIOMARKERS FOR DETERMINING PATIENT RISK OF HEART DISEASE AND NOVEL GENOMIC AND EPIGENOMIC DRUG TARGETS TO DECREASE RISK OF HEART DISEASE AND/OR IMPROVE PATIENT OUTCOME AFTER MYOCARDIAL INFARCTION OR CARDIAC INJURY

Publication No.:  EP4795204A1 26/08/2026
Applicant: 
GUARDANT HEALTH INC [US]
Guardant Health, Inc.
WO_2025085784_PA

Absstract of: WO2025085784A1

Disclosed herein are methods, compositions, and devices for use in diagnosis and treatment of disease, including cardiovascular disease, and such disease and dysfunction as related to cancer therapy administration. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more biomarkers that are indicative of a cardiovascular disease and dysfunction.

Effect evaluation system for resisting chronic heart failure by fish scale protein polypeptide

Publication No.:  CN122638207A 25/08/2026
Applicant: 
HAINAN KANGENMEI BIO TECH CO LTD
\u6D77\u5357\u5EB7\u6069\u7F8E\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
CN_122638207_A

Absstract of: CN122638207A

The invention discloses an anti-chronic heart failure efficacy evaluation system for fish scale protein polypeptides, and relates to the technical field of bioactive polypeptide evaluation and cardiovascular disease function analys.The efficacy evaluation system comprises a raw material processing module used for preparing the fish scale protein polypeptides, a CHF model building module used for animal experiments and a function detection module, and the data processing and analysis module is used for integrating tissue remodeling indexes such as cardiac function, oxidative stress and inflammatory response by adopting multi-dimensional statistics and a visualization algorithm so as to realize comprehensive evaluation on the efficacy of the fish scale protein polypeptide. The method can realize systematic, quantitative and mechanical evaluation of the chronic heart failure resistance of the fish scale protein polypeptide, solves the problems of single evaluation index, poor result repeatability and lack of mechanism association in the prior art, and has the advantages of comprehensive evaluation, reliable result, wide application range and high generalizability.

Pyrosequencing primer pair and kit for detecting ACE genotyping

Nº publicación: CN122629196A 25/08/2026

Applicant:

SHANDONG BAIMAO BIOTECHNOLOGY CO LTD
\u5C71\u4E1C\u767E\u8302\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8

CN_122629196_PA

Absstract of: CN122629196A

The invention belongs to the technical field of in-vitro nucleic acid detection, and discloses a pyrosequencing primer pair and a kit for detecting ACE genotyping, the kit comprises a specific amplification primer group (SEQ ID NO.1-3) and a specific sequencing primer (SEQ ID NO.4), the 5'end of the amplification primer is subjected to biotin labeling, and the kit is matched with blank control and multiple positive control. Based on a pyrosequencing technology, by optimizing primer design and a reaction system, accurate typing of the ACE I/D gene is achieved, and the problems that in the prior art, typing is difficult, misjudgment is prone to occurring, operation is tedious, and the detection period is long are solved. The method has the advantages of high detection sensitivity, strong specificity, realization of the parallel detection of 16-96 samples within 1 hour by only 30 minutes on a single machine, intuitive and accurate result and perfect quality control, is suitable for clinical large-scale sample detection, and has a wide application prospect in hypertension medication guidance and cardiovascular disease risk assessment.

traducir